00:00It's Benzinga, bringing Wall Street to Main Street
00:02Novo Nordisk plans to sell its Wegevy weight-loss drugs on the HIMSS and HERS Health platform,
00:07ending a dispute between the companies that escalated into a legal battle last month,
00:12Bloomberg reported.
00:13Novo sued HIMSS for patent infringement after the telehealth firm launched
00:17and later canceled a $49 copy of Novo's obesity pill.
00:21The U.S. Food and Drug Administration had also threatened action against HIMSS.
00:25The companies plan to announce a new partnership as soon as Monday.
00:28Novo previously ended an agreement to sell Wegevy through HIMSS last year
00:32over marketing tactics and continued sales of Wegevy copies.
00:36HIMSS did not immediately respond to Reuters' request for comment.
00:40For all things money, visit Benzinga.com
Comments